Entries by moonbase alpha

Mission Therapeutics to Present at Conferences in March – April 2016

CAMBRIDGE, UK – 31 March 2016 – MISSION Therapeutics, a drug discovery and development company focused on selectively targeting deubiquitylating enzymes to treat cancer, neurodegenerative and other diseases, today announced that Anker Lundemose, Chief Executive Officer, Dr Xavier Jacq, VP Scientific Affairs, Dr Paul Wallace, Chief Business Officer and Dr Michael Koslowski, Chief Medical Officer […]

Mission Therapeutics to Present at Conferences in March 2016

 CAMBRIDGE, UK – 1 March 2016 – MISSION Therapeutics, a drug discovery and development company focused on selectively targeting deubiquitylating enzymes to treat cancer, neurodegenerative and other diseases, today announced that Anker Lundemose, Chief Executive Officer, and Dr Xavier Jacq, VP Scientific Affairs, are scheduled to present at the following events: (1) 6th Ubiquitin Research […]

MISSION Therapeutics Raises £60 million to Progress Development of Novel DUB Inhibitors from Innovative Drug Platform

Woodford Patient Capital Trust joins existing syndicate supporting transition to clinical development  CAMBRIDGE, UK – 2 February 2016 – MISSION Therapeutics, a drug discovery and development company focused on selectively targeting deubiquitylating enzymes to treat cancer, neurodegenerative and other diseases, today announced it has raised £60 million. The financing was jointly led by Imperial Innovations […]

MISSION Therapeutics appoints David Luther as Chief Financial Officer

Expands management team with accomplished senior executive CAMBRIDGE, UK – 1 October 2015 – MISSION Therapeutics, a drug discovery and development company focused on selectively targeting deubiquitylating (DUB) enzymes to treat cancer and other diseases, announced the appointment of David Luther as Chief Financial Officer, to take effect from 1st October 2015. Mr Luther brings more […]

MISSION Therapeutics receives funding from Innovate UK for DUB cancer programme

CAMBRIDGE, UK – 22 September 2015 – MISSION Therapeutics, a drug discovery and development company focused on selectively targeting deubiquitylating enzymes to treat cancer and other diseases, today announced that it has been awarded a £1.9 million grant from Innovate UK. The funding is for the discovery of preclinical DUB inhibitors directed at specific deubiquitylating […]

MISSION Therapeutics appoints Michael Koslowski as Chief Medical Officer

CAMBRIDGE, UK – 1 September 2015 – MISSION Therapeutics (MISSION), a drug discovery and development company focused on selectively targeting deubiquitylating enzymes to treat cancer and other diseases, today announced the appointment of Dr Michael Koslowski as Chief Medical Officer to take effect from 1 September 2015. Dr Koslowski brings over 15 years’ experience across […]

MISSION appoints Dr Colin Goddard to its Board of Directors

CAMBRIDGE, UK,  1ST JULY 2015 – MISSION Therapeutics, a drug discovery and development company today announced Dr Colin Goddard, former Chief Executive Officer of OSI Pharmaceuticals (“OSI”), has been appointed to the Company’s Board of Directors. “We are privileged to have Dr Goddard join our board at this exciting phase of MISSION’s growth and development”, […]

Prof Steve Jackson to give Sackler Lecture

Professor Steve Jackson, MISSION Therapeutics CSO and Professor of Biology, Head of Cancer Research UK laboratories at the Gurdon Institute, University of Cambridge, will be giving the 22nd Raymond and Beverly Sackler distinguished lecture on the 11th of June in Leeds and on the 25th of June in Cambridge. The title of the lecture is […]

MISSION Therapeutics presents at AACR the identification of novel inhibitors of the UCHL1 oncogene

Cambridge UK, 20 April 2015 – MISSION Therapeutics, a company focused on the discovery and development of modulators of the deubiquitylating (DUB) enzyme family for the treatment of cancer and other diseases, today presents a poster at AACR entitled “Discovery of highly selective UCHL1 inhibitors with in vivo pre-clinical anti-tumour activity”. UCHL1 is a prototypical […]

MISSION Therapeutics wins new Life Science Innovation Award

Recognition of outstanding progress in hitherto challenging therapeutic target area Cambridge UK, 20 March 2015 – MISSION Therapeutics, a company focused on the discovery and development of modulators of the deubiquitylating (DUB) enzyme family for the treatment of cancer and other diseases, today announces that it has won the new Life Science Innovation Award at […]